Actively Recruiting
EXActDNA-003 NSABP B-64 Validating a Blood Test to Predict Recurrence in High-Risk Early Breast Cancer Treated with Neoadjuvant Chemotherapy
Led by Exact Sciences Corporation · Updated on 2026-10-27
1800
Participants Needed
61
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are enrolling adults with high-risk early breast cancer who plan to undergo chemotherapy to study molecular residual disease MRD detection using circulating tumor DNA ctDNA analysis. This observational study aims to predict cancer recurrence by analyzing blood and tissue samples over a follow-up period of up to 5.5 years. The study is sponsored by Exact Sciences Corporation and focuses on participants with invasive breast cancer undergoing neoadjuvant therapy. Participants will provide blood and tissue samples to perform a ctDNA MRD test. The study collects residual tissue from biopsies and blood draws totaling 34 cc per research visit. There is no intervention or treatment assigned instead, the study observes and analyzes samples to validate the tests ability to detect molecular residual disease after chemotherapy. During the study, participants undergo blood sample collections and provide available residual tissue from diagnostic biopsies. Researchers will measure outcomes such as biopsy tissue evaluability and distant recurrence-free intervals at 3 to 6 years. Additional outcomes include tumor mutation prevalence, test sensitivity and specificity, and survival intervals. Participants will be followed for several years to monitor cancer recurrence and survival, with no active treatment administered as part of the study.
CONDITIONS
Brief Title
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Research Team
N
NSABP Department of Site and Study Management Department of Site and Study Management
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here